Group 1 - Morgan Stanley's fund manager Wang Dapeng expresses optimism about the pharmaceutical industry, highlighting its potential for innovation, manufacturing, and consumption upgrades [1][3] - The second quarter report shows a strong performance in the equity market, with a focus on A-share and Hong Kong stock innovative drugs, benefiting from better-than-expected business development in representative innovative drug companies [2][3] - The top ten holdings of the fund as of June 30, 2025, include companies like Innovent Biologics and BeiGene, accounting for 79.90% of the fund's net asset value, an increase of over 11 percentage points from the previous quarter [2] Group 2 - The pharmaceutical sector is expected to benefit from a stable growth trend in medical insurance and supportive policies for innovative drug payments, leading to a return to endogenous growth [3] - Policy support includes increased pensions and healthcare subsidies, as well as ongoing normalization of centralized procurement and industry restructuring, which are expected to favor the development of innovative drugs [3] - Long-term growth in the pharmaceutical industry is anticipated due to factors such as an aging population, rising income levels, and increased health awareness, with expected growth rates surpassing GDP growth [3]

Core Viewpoint - The article emphasizes the importance of "economic resilience" in the context of global industrial chain restructuring and the ongoing US-China competition, suggesting that this resilience is crucial for entrepreneurs to innovate and reconstruct competitive advantages [3]. Group 1: Economic Resilience - Economic resilience has become a core theme in major power competition, serving as a strategic foundation for entrepreneurs to innovate and gain competitive advantages [3]. - The article references Japan's experience during its "lost three decades," highlighting how its long-standing companies have developed resilience through cultural integration, risk diversification, and avoiding chaotic expansion [3]. Group 2: Learning Journey - The article introduces a six-day, five-night study tour in Japan, designed to explore the resilience of Japanese businesses and their growth models, which are particularly relevant for Chinese entrepreneurs [3][4]. - Participants will visit five Japanese companies across various sectors, including healthcare, precision manufacturing, and sustainable development, to understand their strategies for overcoming low-growth challenges and aging population issues [7]. Group 3: Knowledge Sharing - The study tour includes sessions with industry experts discussing key topics such as value creation in low-growth environments and global branding strategies, aiming to provide a systematic understanding of how to balance technology and innovation [16]. - The program will take place partly at the University of Tokyo, allowing participants to engage in a rich academic environment while learning from real-world business cases [16]. Group 4: Cultural Experience - The tour incorporates cultural experiences, such as tea ceremonies and traditional crafts, to deepen participants' understanding of Japanese business resilience and foster connections among diverse professionals [21]. - The concept of "一期一会" (ichigo ichie), which emphasizes the uniqueness of each encounter, is highlighted as a guiding principle for the study tour, encouraging participants to value their interactions and shared experiences [21].

Core Viewpoint - The recent growth of certain equity funds by billions is notable, especially in the context of a generally poor performance in equity investments over recent years. This contrasts sharply with the booming market four years ago when new fund issuances often exceeded hundreds of billions [1]. Group 1: Fund Company Scale - As of April 25, the number of public fund companies in China has reached 200, with seven companies in the "trillion yuan club," including E Fund, Huaxia, and GF Fund, among others [1]. - The top 20 public fund companies by total assets have a minimum threshold of over 600 billion yuan [2]. Group 2: Non-Money Market Fund Scale - The top five companies by non-money market fund scale are E Fund (1.36 trillion yuan), Huaxia (1.19 trillion yuan), GF Fund (0.79 trillion yuan), and others, indicating a significant variation in rankings compared to total asset rankings [3][4]. - Among the top 20 companies, 19 have non-money market fund scales exceeding 300 billion yuan, with only one company, Xingzheng Global Fund, below this threshold [4]. Group 3: Non-Money Market Fund Proportion - The top five companies by non-money market fund proportion are Huatai-PB (90.15%), Jingshun Great Wall (70.14%), and others, highlighting a shift in focus towards non-money market assets [6][7]. - All top 20 companies have a non-money market fund proportion above 50%, indicating a strong emphasis on these assets among leading fund companies [7]. Group 4: Recent Performance of Fund Products - The analysis of fund performance over the past six months shows that the top-performing products are diversified across various themes, including artificial intelligence, North Exchange-listed companies, and gold ETFs [9][10][13]. - The top five products by performance include E Fund's advanced manufacturing fund with a return of 93.74%, and Penghua's carbon neutrality fund with 87.67% [9].

以下文章来源于清科沙丘投研院 ，作者清科沙丘投研院 清科沙丘投研院 . 清科创业（1945.HK）旗下高端投资培训品牌，致力于培养拥有全球视野、擅于捕捉中国市场机会、具 有超强实战经验的投资家。 低增长存量时代，我们该向日本学什么？ 当中国进入经济增速换挡期，老龄化加剧、消费需求迭代、产业升级迫在眉睫，如何突破增长瓶 颈？ 当我们望向东方，相似的经济周期，邻国日本早已给出答案—— 在东京丸之内热闹的十字路口，繁华与喧嚣的表象之下，日本企业正以特有的韧性演绎着另一种叙 事： 超 2.5 万家百年企业仍在迭代 基业长青 的密码， 精益创新 的制造业持续书写 " 隐形冠军 " 的 神话，老龄化社会不断转化为万亿级 银发经济 的创新试验田 …… 为探寻其中的破局之道，沙丘投研院重磅推出 「韧性破局·揭秘日本模式 探寻中国增长」 日本深 度游学，6天5晚，深度串联东京与京都，探访标杆企业，对话一线创投大咖，解码低增长时代的 韧性基因，共同书写当下中国企业家最需要的"生存指南"。 拖至文末点击 「阅读原文」 报名 行行行行行程程程程程亮亮亮亮亮点点点点点 11111 高效学习，必须要身临其境 6月9日至14日 日本·东京 ...